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Background: Malignant tumors are the single most common cause of death and the mortality rate of ovarian
cancer is the highest among gynecological disorders. The excision of benign tumors is generally followed by
complete recovery; however, the activity of cancer cells often results in rapid proliferation even after the tumor has
been excised completely. Thus, clinical treatment must be supplemented by auxiliary chemotherapy or
radiotherapy. Sulforaphane (SFN) is an extract from the mustard family recognized for its anti-oxidation abilities,
phase 2 enzyme induction, and anti-tumor activity.
Methods: This study investigated the cell cycle arrest in G2/M by SFN and the expression of cyclin B1, Cdc2, and
the cyclin B1/CDC2 complex in PA-1 cells using western blotting and co-IP western blotting.
Results: This study investigated the anticancer effects of dietary isothiocyanate SFN on ovarian cancer, using cancer
cells line PA-1. SFN-treated cells accumulated in metaphase by CDC2 down-regulation and dissociation of the cyclin
B1/CDC2 complex.
Conclusion: Our findings suggest that, in addition to the known effects on cancer prevention, SFN may also
provide antitumor activity in established ovarian cancer.
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Isothiocyanates (ITCs) are naturally occurring compo-
nents of vegetables that have demonstrated biological
activity against carcinogenesis as well as chemopre-
ventive properties [1]. It has been suggested that in
conjunction with chemotherapy, ITCs may enhance
drug sensitivity [2]. Sulforaphane (SFN), a potent can-
cer preventive agent, is a dietary isothiocyanate found
as a precursor glucosinolate in cruciferous vegetables
such as Brussels sprouts, cauliflower and broccoli [3].
Interest in this agent has grown in recent years due
to its putative beneficial pharmacological effects as an
antioxidant [4], anti-inflammatory [5] and antitumor
agent [6]. SFN is also a potent scavenger of reactive
oxygen species (ROS), including superoxide anions* Correspondence: ed101779@edah.org.tw; jenway@mail.cjcu.edu.tw
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reproduction in any medium, provided the orand hydroxyl radicals [7]. Many studies have indicated
an inverse correlation between the consumption of
cruciferous vegetables and a decrease in the incidence
of various tumors, including those of the prostate [8],
cervical [9], colorectal [10], and lung [11]. In addition
to inhibiting cell proliferation and increasing apop-
tosis [10], other mechanisms have also been proposed
to explain the anti-carcinogenic effects of SFN. These
include anti-inflammatory and antioxidative activities,
the induction of phase 2 detoxification enzymes, the
inhibition of cyclooxygenase 2 (COX-2) [12], and the
effect on protein kinases [13].
This study investigated the influence of SFN on ova-
rian cancer cell lines (PA-1) with regard to the anti-
proliferation of PA-1 cells and induced cell cycle arrest
in the G2/M phase. These results may provide support
for the chemoprevention of ovarian cancer.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




butane], DMSO (dimethyl sulfoxide) and MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide],
were obtained from Sigma (St Louis, MO). All other re-
agents and compounds were analytical grade.
Cell culture
PA-1 cells were purchased from the Food Industry
Research and Development Institute (Hsinchu, Taiwan).
The cells were maintained in flasks containing MEM
supplemented with 10% (v/v) FBS and cultured in an incu-
bator at 37°C with an atmosphere containing 5% CO2.
Cell proliferation assay
Cells were seeded into 96-well culture plates at 10,000
cells/well and treated with SFN. One to three days (0 μMFigure 1 SFN mediates the survival of PA-1 cells, and thus inhibits pr
PA-1 cells with increasing doses of SFN for 24 to 72 hours. The surviva
method; (B) Influence of SFN on apoptosis in PA-1 cells; (C) Total apoptosi
activation in PA-1 cells following SFN treatment. After being treated with S
(pro-caspase 3) were quantified using an Li-COR near infrared imaging syst
& and # in each group of bars indicate that the differences resulting from tSFN was the control group.) MTT dye (1 mg/ml) was
added to each well 4 hours following treatment. The reac-
tion was stopped by the addition of DMSO, and OD540
was measured using a multi-well plate reader (Powerwave
XS, Biotek). In the absence of cells, the background ab-
sorbance of the medium was subtracted. Results were
expressed as a percentage of the control, which was con-
sidered to be 100%. Each assay was performed in triplicate
and the results were expressed as the mean (+/−SEM).
Measurement of apoptosis
PA-1 cells were first seeded in 6-well plates (Orange
Scientific, E.U.). Following treatment with SFN for four
hours, the supernatant was discarded and cells were
harvested and re-centrifuged. Cells were subsequently
resuspended/incubated in 1X annexin-binding buffer
(5 μL of annexin V-FITC [BD Pharmingen, BD, USA] and
1 μL of 100 μg/mL PI working solution) for 15 minutes.oliferation: (A) In vitro study was initiated by treating each of the
l of these SFN-treated cancer cells was then measured using the MTT
s in PA-1 cells after 4 h of incubation with SFN; (D) Caspase-3
FN, cells underwent western blot analysis and band intensities
em. Statistical analysis was performed using a t-test; the symbols *,
reatment with SFN are statistically significant at P < 0.05.
Figure 2 Influence of SFN on cell cycle progression/distribution in PA-1 cells: (A) Cell cycle analysis of PA-1 cells after being cultured
with SFN for 24 h; (B) SFN induced an increase in the number of G2/M phase cells (%). The symbols * and & in each group of bars
indicates that the differences resulting from treatment with SFN is statistically significant at P < 0.05.
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using flow cytometry (FACSCalibur, BD, USA). Data was
analyzed usingWinMDI 2.8 free software (BD, USA).
Cell cycle analysis
Cell cycle analysis was performed using fluorescent nucleic
acid dye and propidium iodide (PI) to identify the proportion
of cells in each of the three stages of interphase. Cells were
treated with SFN for 24 hours, and subsequently harvested
and fixed in 1ml of cold 70% ethanol for at least eight hours
at −20°C. DNA was stained in PI/RNaseA solution and
the DNA content was detected using flow cytometry. Data
was analyzed using WinMDI 2.8 free software (BD, USA).Western blot assay
A total of 30–50 μg of proteins were separated by 10% SDS-
PAGE and transferred to PVDF membranes (Millipore,
USA). The membranes were blocked with blocking buffer
(Odyddey, USA) overnight and subsequently incubated
with anti-β-actin (Sigma-Aldrich, St. Louis, MO, USA),
anti-CDC2, anti-caspase 3, and anti-cyclin B1 (Santa Cruz
BioTechnology, USA) antibodies for 1.5 ~ 2 hours. The
blots were then washed and incubated with a second anti-
body (IRDye Li-COR, USA) at a dilution of 1/20,000 for
30 minutes. Finally, the antigen was visualized using a near
infrared imaging system (Odyssey LI-COR, USA) and data
was analyzed usingOdyssey 2.1 software.
Figure 3 Cell cycle arrest by SFN in PA-1 cells via inhibition of CDC2. Cells were treated with SFN followed by (A) western blot analysis
(B) quantification of intensities by Li-COR near infrared imaging system. Significant differences were determined at a level of *P < 0.05
versus the 0 μM control group.
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Co-IP is an effective means of quantifying protein-protein
interaction in cells. Briefly, 500 μg of cellular proteins were
labeled using anti-cyclin B1 (Santa Cruz BioTechnology,
USA) following overnight incubation at room tempe-
rature. The protein-antibody immunoprecipitates were
collected by protein A/G plus-agarose (Santa Cruz Bio-
Technology, USA). Following the final wash, the samples
were boiled and centrifuged to pellet the agarose beads.
Western blot analysis of the CDC2 protein in the super-
natant was then conducted. Antigens were visualized
using a near infrared imaging system (Odyssey LI-COR,
USA) and data was analyzed using Odyssey 2.1 software.Statistical analysis
All data was reported as the mean (±SEM) of at
least three separate experiments. A t-test or one-way
ANOVA with post-hoc test was employed for statis-
tical analysis, with significant differences determined
as P < 0.05.
Results
SFN inhibits proliferation of PA-1 cells
We hypothesized that SFN could mediate the survival
of PA-1 cells and thus inhibit their growth. To explore
the anti-tumor activity of SFN against PA-1 cells, an
in vitro cell viability study was conducted in which
Figure 4 Mitosis delay by SFN in PA-1 cells via inhibition of Cdc2-cyclin B1 complex dissociation: Cells were treated with SFN followed
by (A) Co-IP and western blot analysis, and (B) quantification of intensities by Li-COR near infrared imaging system. Significant
differences were determined at a level of *P < 0.05 versus the 0 μM control group.
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creasing doses of SFN (0, 6.25, and 12.5 μM) for 24 to
72 hours. The results in (Figure 1A) indicate that the
survival and proliferation of PA-1 cells were decreased
by treatment with SFN in a dose-dependent (The
24 hours’ IC50 of simvastatin in the PA-1 cancer cells
was determined to be 17.083 μM; y = −2.8213× +
98.199, R2 = 0.9697) (*p < 0.05 vs SFN 0 μM group)
and time-course manner (& p < 0.05 vs 24 hour treat-
ment, # p < 0.05 vs 48 hour treatment).
SFN repressed the cell viability of PA-1 cells without
apoptosis induction
A study on apoptosis was performed to further elucidate
anti-cancer mechanisms of SFN in PA-1 cells. After
treating the cells with various doses of SFN, the percent-
age of apoptotic cells was assessed using Annexin V-
FITC and propidium iodide staining, followed by flow
cytometric analysis (Figure 1B). A dot-plot of AnnexinV-FITC fluorescence versus PI fluorescence also indi-
cated a non-significant increase in the percentage of
apoptotic cells treated with SFN. At SFN concentrations
of 6.25 to 12.5 μM, no significant increase was observed
in the percentage of cells undergoing necrosis and
apoptosis (Figure 1C) or caspase 3 activation (Figure 1D).
The results summarized in Figure 1 indicate that SFN
may mediate the survival of PA-1 cells and thus inhibit
their proliferation without apoptosis induction.
SFN treatment induced the accumulation of G2/M phase
in PA-1 cells
The cell-cycle distribution of SFN-treated PA-1 cells was
analyzed using flow cytometry. Prior to processing and
analysis, cells were exposed to SFN for a total of
24 hours. As shown in Figure 2A, the cells exposed to
SFN showed an increase in the number of cells in the
G2/M phase (& p < 0.05 vs SFN 0 μM), compared with
the number of untreated cells. This could imply that the
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that treatment with SFN simultaneously reduced the
number of cells in the G1 phase (* p < 0.05 vs SFN 0 μM)
(Figure 2B).
Cell cycle arrest by SFN in PA-1 cells via CDC2 down
regulation and dissociation of the cyclin B1/CDC2
complex
Figure 3 illustrates the immunoblotting of cellular proteins
from PA-1 cells treated with SFN, revealing a decrease in
CDC2 following incubation with SFN (Figure 3A). Cyclin
B1 and CDC2 protein expression was quantified by
measuring relative intensities. We found that CDC2
levels were significantly lower in cells incubated with
SFN concentrations of 12.5 μM (Figure 3B). Moreover,
the activity of the cyclin B1/CDC2 complex (important for
G2-M transition during the cell cycle) was determined by
Co-IP (Figure 4A) and quantified by measuring relative
band intensities. We found that cyclin B1/CDC2 complex
activity was significantly suppressed in cells incubated
with an SFN concentration of 12.5 μM (Figure 4B).
These results indicate an increase of the cell popula-
tion in G2/M phase via a down regulation of CDC2 and
dissociation of the cyclin B1/CDC2 complex following
incubation with SFN in PA-1 cells.
Discussion
The results collected in this study using cell lines of
human ovarian cancer provide experimental evidence
indicating that SFN may induce irreversible cell cycle ar-
rest during the G2/M phase. These dietary constituents
demonstrate chemopreventive and chemotherapeutic
potential through their ability to ameliorate the side ef-
fects of conventional chemotherapy [14].
This study investigated the in vitro expression of cyclin
B1 and Cdc2 in PA-1 cells. The cells possess me-
chanisms to maintain genomic stability through cell
cycle arrest [15]. At least two cell cycle checkpoints play
a role in the cellular response, allowing the DNA to be
repaired prior to DNA duplication (G1/S checkpoint) or
mitosis (G2/M checkpoint) [16]. Cdc2 regulates mitosis
and binds to cyclin B to form mitosis-promoting factor
(MPF) [17]. The activity of MPF is regulated by the
phosphorylation/dephosphorylation of Cdc2 as well as
the accumulation of cyclin B protein and p53; GADD45
is also involved in a G2/M checkpoint and may partici-
pate in the regulation of Cdc2 kinase activity [18,19].
Other lines of evidence suggest that DNA damage ex-
cludes cyclin B1 from the nucleus, which promotes G2
arrest [20]. It is possible that cell cycle checkpoints delay
cell cycle progression to allow additional time for the
repair of DNA damage; however, our study found no dir-
ect evidence that DNA was repaired while the cells were
arrested at the checkpoint.Recent studies have shown that SFN inhibits the growth
of tumor precursors and tumors in mice models when
treatment is initiated at the time of carcinogen administra-
tion [10]. The co-inhibition of PI3K/AKT and ERK path-
ways activates FOXO transcription factor and enhances
SFN-induced FOXO transcriptional activity, leading to cell
cycle arrest and apoptosis [21].
Conclusions
We conclude that G2 delay is a common response of
tumor cells to chemotherapy with SFN. We further
propose that mechanisms of this delay may be reduced
expression of CDC2 and dissociation of the cyclin B1/
CDC2 complex. Therefore, although certain chemopre-
ventive effects of SFN and related isothiocyanate com-
pounds have already been established with regard to
ovarian cancer cells, SFN should be investigated further
to confirm the additional antitumor properties proposed
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